fashion -WSS

fashion

author：leisure time 2025-09-28 02:27:31 - browse：535

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： An inside look at PIPEs, biotech's buzzy new financing tool

focus

WSS

RSV vaccines may be linked to small increased risk of developing GBS

Why getting cancer drugs just got harder for rural patients

SCOTUS questions limit to govt efforts to fight misinformation

Neuroscience’s long legacy of racism

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Asbestos, a deadly carcinogen, banned by EPA

leisure time

fashion

entertainment

Cancer drug shortages should be causing more outrage

Orchard's therapy for neuron disease in children wins FDA approval

Psychedelics group wrestles with new pharma identity

Clinical trials giant ICON acquires HumanFirst

Guidelines to prevent youth baseball injuries need more muscle

AstraZeneca to buy developer of next

After affirmative action ruling, medical educators look to 'holistic review'

Virtual Event: March of the Biosimilars

Wildfire smoke exposes gaps in outdoor worker protections

Virtual Event: March of the Biosimilars

hotspot

Creating egg and sperm cells from stem cells raises ethical issues

Kenai launches with $82 million for Parkinson’s stem cell therapy

Leading voice in opioid treatment defends methadone clinic system

International team creates first chimeric human

Obesity now affects over 1 billion people worldwide, study finds

Kenai launches with $82 million for Parkinson’s stem cell therapy

focus

focus

focus

hotspot